Erythromycin bioactivity is stable in ophthalmic ointment used for prophylaxis of neonatal gonococcal conjunctivitis.
Erythromycin ophthalmic ointment (E. Fougera & Co., Melville, N.Y.) and erythromycin gluceptate standards prepared in ointment base were stored at room temperature and heated at temperatures up to 45 degrees C for as long as 6 h before being assayed for bioactivity. We were unable to detect any significant loss of antibiotic bioactivity.
D003234:Conjunctivitis, Bacterial / Q000517:prevention & control*; D004349:Drug Packaging; D004355:Drug Stability; D004917:Erythromycin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006069:Gonorrhea / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D008826:Microbial Sensitivity Tests; D009824:Ointments; D009883:Ophthalmic Solutions; D013594:Syringes
D009824:Ointments; D009883:Ophthalmic Solutions; D004917:Erythromycin